FDA DEVICE FACTS
DIAM™ Spinal Stabilization System
Companion Spine France Sas
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
The DIAMTM Spinal Stabilization System is indicated for skeletally mature patients that have moderate to severe primary low back pain (greater than leg pain) secondary to lumbar degenerative disc disease (DDD), at a single level from L2 -L5 with current episode refractory to at least 6 months non-operative care.
Symptomatic disc disease is confirmed by patient history, physical examination, and radiographic evaluation with one or more of the following factors:
• Greater than 2mm of decreased disc height (average disc height) compared to the adjacent level
• Scarring/thickening of the ligamentum flavum, annulus fibrosus, or facet joint capsule
• Non-extruded herniated nucleus pulposus
The DIAM™ device is implanted via a minimally invasive posterior approach.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。